| Today’s Big NewsApr 11, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
| By Angus Liu The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea. |
|
|
|
By Max Bayer Chinese biotechs have never had so much success inking cross-region out-licensing deals. But could an increase in national security dampen the scorching-hot space? |
By Conor Hale The process, being developed by First Ascent Biomedical, showed promise in a small study published this week in Nature Medicine. |
By Max Bayer Vertex is buying Alpine Immune Sciences for $4.9 billion, the companies announced Wednesday. At the center of the deal is Alpine's midstage IgA nephropathy treatment. |
|
Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now.
|
|
By Fraiser Kansteiner The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S. as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Fraiser Kansteiner Fujifilm Diosynth is investing $1.2 billion more to soup up its end-to-end biomanufacturing facility in Holly Springs, North Carolina, bringing the total project to more than $3.2 billion, the company said Thursday. The latest expansion is expected to create 680 new jobs. |
By Conor Hale Collectively known as the HuFriedyGroup, the 1,500-employee international division manufactures dental instruments, infection prevention products and patient sedation systems, including the long-time brands of Hu-Friedy, Crosstex, Omnia and Accutron. |
By Nick Paul Taylor Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients. |
By Andrea Park Castle Biosciences is giving Esophageal Cancer Awareness Month the royal treatment, spending April sponsoring a series of events and initiatives to improve education, prevention and research around the condition. |
By Conor Hale After more than a year in the works, Roche and Eli Lilly have taken a step closer to delivering their blood test to help diagnose Alzheimer’s disease. |
By Zoey Becker The company's planned site is now on the back burner after a lack of vaccine demand from Africa and cancelled orders have stacked up to more than $1 billion in losses, Moderna said in a statement. |
By Gabrielle Masson On the heels of Relyvrio’s market withdrawal in amyotrophic lateral sclerosis, Amylyx Pharmaceuticals has shared early data from a phase 2 trial in a separate rare disease that the biotech is touting as “clinically meaningful.” |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now.
|
|
| eBookUnlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
